The aim of this study was to determine the changes in serum levels of resistin, apelin, and visfatin in patients with severe obesity before and after laparoscopic sleeve gastrectomy (LSG) and to examine the relationship between weight loss and these adipokines.
Materials and Methods:
The serum levels of resistin, visfatin, and apelin were measured in 44 severely obese patients who underwent LSG. Blood samples were collected before surgery and at 3 months after the surgery along with anthropometric measurements and insulin resistance determined by homeostasis model assessment (HOMA-IR).
Results:
Significant decreases in body–mass index (p < 0.001) and HOMA-IR (p = 0.020) were achieved at 3 months after the surgery. While postop serum resistin levels increased compared with preop values (p < 0.001), serum apelin levels were found to be lower after surgery (p = 0.030), and there was no statistically significant difference between preop and postop serum visfatin concentrations (p = 0.255). No correlation was found between weight loss and serum adipokine levels.
Conclusions:
LSG is an effective procedure for losing weight and reducing insulin resistance in a short period of time; however, further studies are needed to understand the role of these adipokines in regulation and/or dysregulation of obesity.
Get full access to this article
View all access options for this article.
References
1.
SatmanI, OmerB, TutuncuY, et al.Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol, 2013; 28(2):169–180; doi:10.1007/s10654-013-9771-5.
2.
FruhSM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract, 2017; 29(S1):S3–S14; doi:10.1002/2327-6924.12510.
3.
CefaluWT, BrayGA, HomePD, et al.Advances in the science, treatment, and prevention of the disease of obesity: Ref lections from a diabetes care editors' expert forum. Diabetes Care, 2015; 38(8):1567–1582; doi:10.2337/dc15-1081.
4.
HausmanDB, DiGirolamoM, BartnessTJ, et al.The biology of white adipocyte proliferation. Obes Rev, 2001; 2(4):239–254; doi:10.1046/j.1467-789X.2001.00042.x.
5.
SkurkT, Alberti-HuberC, HerderC, et al.Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 2007; 92(3):1023–1033; doi:10.1210/jc.2006-1055.
HolcombIN, KabakoffRC, ChanB, et al.FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J, 2000; 19(15):4046–4055; doi:10.1093/emboj/19.15.4046.
8.
SteppanCM, BaileyST, BhatS, et al.The hormone resistin links obesity to diabetes. Nature, 2001; 409:307–312; doi:10.1016/j.reuma.2008.12.003.
9.
SchwartzDR, LazarMA. Human resistin: Found in translation from mouse to man. 2012; 22(7):259–265; doi:10.1016/j.tem.2011.03.005.Human.
10.
KuklaM, MazurW, BuldakRJ, et al.Potential role of leptin, adiponectin and three novel adipokines—Visfatin, chemerin and vaspin—in chronic. Mol Med, 2011; 17(11–12):1397–1410; doi:10.2119/molmed.2010.00105.
11.
FukuharaA, MatsudaM, NishizawaM, et al.Visfatin: A protein secreted by visceral fat that Mimics the effects of insulin. Science (80−), 2005; 307(5708):426–430; doi:10.1126/science.1097243.
12.
O'CarrollAM, LolaitSJ, HarrisLE, et al.The apelin receptor APJ: Journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol, 2013; 219(1); doi:10.1530/JOE-13-0227.
13.
YueP, JinH, AillaudM, et al.Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab, 2010; 298(1); doi:10.1152/ajpendo.00385.2009.
14.
ZhuS, SunF, LiW, et al.Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem, 2011; 353(1–2):305–313; doi:10.1007/s11010-011-0799-0.
15.
MatthewsDR, HoskerJR, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diebetologia, 1985; 28(7):412–419; doi:10.1007/BF00280883.
16.
CaparrósP, GómezI, OrtegaG, et al.Resistin in morbidly obese patients before and after gastric bypass surgery. Nutr Hosp, 2017; 34(6):1333–1337; doi:10.20960/nh.1028.
17.
EdwardsC, HindleAK, FuS, et al.Downregulation of leptin and resistin expression in blood following bariatric surgery. Surg Endosc, 2011; 25(6):1962–1968; doi:10.1007/s00464-010-1494-z.
18.
Jankiewicz-WikaJ, KołomeckiK, JacekC, et al.Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbidly obese patients. Endokrynol Pol, 2011; 62(2):109–119; doi:10.1210/en.2011-1427.
19.
SantoroS, MilleoFQ, MalzoniCE, et al.Enterohormonal changes after digestive adaptation: Five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg, 2008; 18(1):17–26; doi:10.1007/s11695-007-9371-0.
20.
MoschenAR, MolnarC, WolfAM, et al.Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression q. J Hepatol, 2009; 51(4):765–777; doi:10.1016/j.jhep.2009.06.016.
21.
PatelL, BuckelsAC, KinghornIJ, et al.Resistin is expressed in human macrophages and directly regulated by PPAR c activators. Biochem Biophys Res Commun, 2003; 300(2):472–476; doi:10.1016/s0006-291x(02)02841-3.
22.
MenzaghiC, CocoA, SalveminiL, et al.Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic caucasians. J Clin Endocrinol, 2015; 91(7):2792–2795; doi:10.1210/jc.2005-2715.
23.
FilkováM, HaluzíkM, GayS, et al.The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol, 2009; 133(2):157–170; doi:10.1016/j.clim.2009.07.013.
24.
Botella-CarreteroJI, Luque-RamírezM, Álvarez-BlascoF, et al.The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg, 2008; 18(8):1000–1006; doi:10.1007/s11695-007-9369-7.
25.
FriebeD, NeefM, KratzschJ, et al.Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia, 2011; 54(5):1200–1211; doi:10.1007/s00125-010-2042-z.
26.
Hosseinzadeh-AttarMJ, GolpaieA, JananiL, et al.Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects. Obes Facts, 2013; 6(2):193–202; doi:10.1159/000351162.
27.
BoucherJ, MasriB, GuigneC, et al.Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocr Soc, 2015; 146(March):1764–1771; doi:10.1210/en.2004-1427.
28.
SoriguerF, Garrido-sanchezL, Garcia-serranoS, et al.Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg, 2009; 19(11):1574–1580; doi:10.1007/s11695-009-9955-y.
29.
KhajehE, PanahiN, GolpaieA, et al.Plasma apelin and asymmetric dimethylarginine (ADMA) levels shortly after laparoscopic greater curvature plication. Obes Surg, 2017; 27(6):1596–1603; doi:10.1007/s11695-016-2509-1.
30.
FasshauerM, BlüherM. Adipokines in health and disease. Trends Pharmacol Sci, 2015; 36(7):461–470; doi:10.1016/j.tips.2015.04.014.
